Skip to main content
SpringerLink
Log in

Recurrent Bone Tumors

  • Chapter
Malignant Pediatric Bone Tumors - Treatment & Management

Part of the book series: Pediatric Oncology ((PEDIATRICO))

  • 1086 Accesses

Abstract

Multimodal approach to treatment has led to the dramatically improved outcome of patients with osteosarcoma and Ewing sarcoma. However, despite intensive therapies and incorporation of novel agents in trials, the therapeutic plateau in recurrent osteosarcoma and Ewing sarcoma has not yet been overcome. Cure for these patients remain a daunting challenge with dismal survival rate after relapse despite best efforts. Certain clinical factors help prognosticate quality of relapse of these tumors. Because patient characteristics are different upon disease recurrence, therapeutic approach to these patients vary widely.

Further improvements in outcome for patients with recurrent disease will depend on refinement of therapy using agents with clinical activity based on understanding of tumor biology, and within a trial design that optimally detects drug activity. There is a growing list of targets for osteosarcoma and Ewings sarcoma. A significant biology effort has been established by cooperative groups, as well as preclinical drug evaluation systems created towards more rapid identification and validation of compounds active in osteosarcoma and Ewing sarcoma. High throughput screens of novel agents should accelerate clinical trial development. Finally, there are now various national and international cooperative groups to efficiently test new agents in these rare tumors.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Akiyama T, Dass CR, Choong PF (2008) Novel therapeutic strategy for osteosarcoma targeting osteoclast differentiation, bone-resorbing activity, and apoptosis pathway. Mol Cancer Ther 7(11):3461–3469. doi:10.1158/1535-7163.MCT-08-0530

    CAS  PubMed  Google Scholar 

  • Akiyama T, Choong PF, Dass CR (2010) RANK-Fc inhibits malignancy via inhibiting ERK activation and evoking caspase-3-mediated anoikis in human osteosarcoma cells. Clin Exp Metastasis 27(4):207–215. doi:10.1007/s10585-010-9319-y

    CAS  PubMed  Google Scholar 

  • Al-Faris N, Al Harbi T, Goia C, Pappo A, Doyle J, Gassas A (2007) Does consolidation with autologous stem cell transplantation improve the outcome of children with metastatic or relapsed Ewing sarcoma? Pediatr Blood Cancer 49(2):190–195. doi:10.1002/pbc.21140

    PubMed  Google Scholar 

  • Anderson PM (2003) Effectiveness of radiotherapy for osteosarcoma that responds to chemotherapy. Mayo Clin Proc 78(2):145–146. doi:10.4065/78.2.145

    PubMed  Google Scholar 

  • Anderson P (2006) Liposomal muramyl tripeptide phosphatidyl ethanolamine: ifosfamide-containing chemotherapy in osteosarcoma. Future Oncol 2(3):333–343. doi:10.2217/14796694.2.3.333

    CAS  PubMed  Google Scholar 

  • Anderson P, Nunez R (2007) Samarium lexidronam (153Sm-EDTMP): skeletal radiation for osteoblastic bone metastases and osteosarcoma. Expert Rev Anticancer Ther 7(11):1517–1527. doi:10.1586/14737140.7.11.1517

    CAS  PubMed  Google Scholar 

  • Anderson PM, Wiseman GA, Dispenzieri A, Arndt CA, Hartmann LC, Smithson WA, Bruland OS (2002) High-dose samarium-153 ethylene diamine tetramethylene phosphonate: low toxicity of skeletal irradiation in patients with osteosarcoma and bone metastases. J Clin Oncol 20(1):189–196

    CAS  PubMed  Google Scholar 

  • Anderson PM, Wiseman GA, Erlandson L, Rodriguez V, Trotz B, Dubansky SA, Albritton K (2005) Gemcitabine radiosensitization after high-dose samarium for osteoblastic osteosarcoma. Clin Cancer Res 11(19 Pt 1):6895–6900. doi:10.1158/1078-0432.CCR-05-0628

    CAS  PubMed  Google Scholar 

  • Anderson P, Kopp L, Anderson N, Cornelius K, Herzog C, Hughes D, Huh W (2008) Novel bone cancer drugs: investigational agents and control paradigms for primary bone sarcomas (Ewing’s sarcoma and osteosarcoma). Expert Opin Investig Drugs 17(11):1703–1715. doi:10.1517/13543784.17.11.1703

    CAS  PubMed  Google Scholar 

  • Anderson PM, Meyers P, Kleinerman E, Venkatakrishnan K, Hughes DP, Herzog C, Chou A (2014a) Mifamurtide in metastatic and recurrent osteosarcoma: a patient access study with pharmacokinetic, pharmacodynamic, and safety assessments. Pediatr Blood Cancer 61(2):238–244. doi:10.1002/pbc.24686

    CAS  PubMed  Google Scholar 

  • Anderson PM, Subbiah V, Rohren E (2014b) Bone-seeking radiopharmaceuticals as targeted agents of osteosarcoma: samarium-153-EDTMP and radium-223. Adv Exp Med Biol 804:291–304. doi:10.1007/978-3-319-04843-7_16

    CAS  PubMed  Google Scholar 

  • Asano T, Kleinerman ES (1993) Liposome-encapsulated MTP-PE: a novel biologic agent for cancer therapy. J Immunother Emphasis Tumor Immunol 14(4):286–292

    CAS  PubMed  Google Scholar 

  • Aung L, Gorlick R, Healey JH, Shi W, Thaler HT, Shorter NA, Meyers PA (2003) Metachronous skeletal osteosarcoma in patients treated with adjuvant and neoadjuvant chemotherapy for nonmetastatic osteosarcoma. J Clin Oncol 21(2):342–348

    PubMed  Google Scholar 

  • Bacci G, Ferrari S, Bertoni F, Rimondini S, Longhi A, Bacchini P, Picci P (2000) Prognostic factors in nonmetastatic Ewing’s sarcoma of bone treated with adjuvant chemotherapy: analysis of 359 patients at the Istituto Ortopedico Rizzoli. J Clin Oncol 18(1):4–11

    CAS  PubMed  Google Scholar 

  • Bacci G, Ferrari S, Longhi A, Perin S, Forni C, Fabbri N, Smith KV (2001) Pattern of relapse in patients with osteosarcoma of the extremities treated with neoadjuvant chemotherapy. Eur J Cancer 37(1):32–38

    CAS  PubMed  Google Scholar 

  • Bacci G, Ferrari S, Longhi A, Donati D, De Paolis M, Forni C, Barbieri E (2003) Therapy and survival after recurrence of Ewing’s tumors: the Rizzoli experience in 195 patients treated with adjuvant and neoadjuvant chemotherapy from 1979 to 1997. Ann Oncol 14(11):1654–1659

    CAS  PubMed  Google Scholar 

  • Bacci G, Longhi A, Ferrari S, Mercuri M, Barbieri E, Bertoni F, Picci P (2006) Pattern of relapse in 290 patients with nonmetastatic Ewing’s sarcoma family tumors treated at a single institution with adjuvant and neoadjuvant chemotherapy between 1972 and 1999. Eur J Surg Oncol 32(9):974–979. doi:10.1016/j.ejso.2006.01.023

    CAS  PubMed  Google Scholar 

  • Bacci G, Balladelli A, Forni C, Ferrari S, Longhi A, Benassi MS, Picci P (2007) Adjuvant and neo-adjuvant chemotherapy for Ewing’s sarcoma family tumors and osteosarcoma of the extremity: further outcome for patients event-free survivors 5 years from the beginning of treatment. Ann Oncol 18(12):2037–2040. doi:10.1093/annonc/mdm382

    CAS  PubMed  Google Scholar 

  • Bacci G, Rocca M, Salone M, Balladelli A, Ferrari S, Palmerini E, Briccoli A (2008) High grade osteosarcoma of the extremities with lung metastases at presentation: treatment with neoadjuvant chemotherapy and simultaneous resection of primary and metastatic lesions. J Surg Oncol 98(6):415–420. doi:10.1002/jso.21140

    PubMed  Google Scholar 

  • Bagatell R, Norris R, Ingle AM, Ahern C, Voss S, Fox E, Blaney S (2014) Phase 1 trial of temsirolimus in combination with irinotecan and temozolomide in children, adolescents and young adults with relapsed or refractory solid tumors: a Children’s Oncology Group Study. Pediatr Blood Cancer 61(5):833–839. doi:10.1002/pbc.24874

    CAS  PubMed Central  PubMed  Google Scholar 

  • Barber-Rotenberg JS, Selvanathan SP, Kong Y, Erkizan HV, Snyder TM, Hong SP, Toretsky JA (2012) Single enantiomer of YK-4-279 demonstrates specificity in targeting the oncogene EWS-FLI1. Oncotarget 3(2):172–182

    PubMed Central  PubMed  Google Scholar 

  • Barger AM, Fan TM, de Lorimier LP, Sprandel IT, O’Dell-Anderson K (2007) Expression of receptor activator of nuclear factor kappa-B ligand (RANKL) in neoplasms of dogs and cats. J Vet Intern Med 21(1):133–140

    PubMed  Google Scholar 

  • Barker LM, Pendergrass TW, Sanders JE, Hawkins DS (2005) Survival after recurrence of Ewing’s sarcoma family of tumors. J Clin Oncol 23(19):4354–4362. doi:10.1200/JCO.2005.05.105

    PubMed  Google Scholar 

  • Baust JG, Gage AA (2005) The molecular basis of cryosurgery. BJU Int 95(9):1187–1191. doi:10.1111/j.1464-410X.2005.05502.x

    PubMed  Google Scholar 

  • Bernstein ML, Devidas M, Lafreniere D, Souid AK, Meyers PA, Gebhardt M, Children’s Oncology G. (2006) Intensive therapy with growth factor support for patients with Ewing tumor metastatic at diagnosis: Pediatric Oncology Group/Children’s Cancer Group Phase II Study 9457–a report from the Children’s Oncology Group. J Clin Oncol 24(1):152–159. doi:10.1200/JCO.2005.02.1717

    CAS  PubMed  Google Scholar 

  • Bielack SS, Kempf-Bielack B, Delling G, Exner GU, Flege S, Helmke K, Winkler K (2002) Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol 20(3):776–790

    PubMed  Google Scholar 

  • Bielack SS, Kempf-Bielack B, Branscheid D, Carrle D, Friedel G, Helmke K, Jurgens H (2009) Second and subsequent recurrences of osteosarcoma: presentation, treatment, and outcomes of 249 consecutive cooperative osteosarcoma study group patients. J Clin Oncol 27(4):557–565. doi:10.1200/JCO.2008.16.2305

    PubMed  Google Scholar 

  • Blaney SM, Seibel NL, O’Brien M, Reaman GH, Berg SL, Adamson PC, Balis FM (1997) Phase I trial of docetaxel administered as a 1-h infusion in children with refractory solid tumors: a collaborative pediatric branch, National Cancer Institute and Children’s Cancer Group trial. J Clin Oncol 15(4):1538–1543

    CAS  PubMed  Google Scholar 

  • Brenner JC, Feng FY, Han S, Patel S, Goyal SV, Bou-Maroun LM, Chinnaiyan AM (2012) PARP-1 inhibition as a targeted strategy to treat Ewing’s sarcoma. Cancer Res 72(7):1608–1613. doi:10.1158/0008-5472.CAN-11-3648

    CAS  PubMed Central  PubMed  Google Scholar 

  • Briccoli A, Rocca M, Ferrari S, Mercuri M, Ferrari C, Bacci G (2004) Surgery for lung metastases in Ewing’s sarcoma of bone. Eur J Surg Oncol 30(1):63–67

    CAS  PubMed  Google Scholar 

  • Briccoli A, Rocca M, Salone M, Guzzardella GA, Balladelli A, Bacci G (2010) High grade osteosarcoma of the extremities metastatic to the lung: long-term results in 323 patients treated combining surgery and chemotherapy, 1985–2005. Surg Oncol 19(4):193–199. doi:10.1016/j.suronc.2009.05.002

    PubMed  Google Scholar 

  • Burdach S, Jurgens H, Peters C, Nurnberger W, Mauz-Korholz C, Korholz D et al (1993) Myeloablative radiochemotherapy and hematopoietic stem-cell rescue in poor-prognosis Ewing’s sarcoma. J Clin Oncol 11(8):1482–1488

    CAS  PubMed  Google Scholar 

  • Burdach S, van Kaick B, Laws HJ, Ahrens S, Haase R, Korholz D, el Go U (2000) Allogeneic and autologous stem-cell transplantation in advanced Ewing tumors. An update after long-term follow-up from two centers of the European Intergroup study EICESS. Stem-Cell Transplant Programs at Dusseldorf University Medical Center, Germany and St. Anna Kinderspital, Vienna, Austria. Ann Oncol 11(11):1451–1462

    CAS  PubMed  Google Scholar 

  • Burdach S, Meyer-Bahlburg A, Laws HJ, Haase R, van Kaik B, Metzner B, Juergens H (2003) High-dose therapy for patients with primary multifocal and early relapsed Ewing’s tumors: results of two consecutive regimens assessing the role of total-body irradiation. J Clin Oncol 21(16):3072–3078. doi:10.1200/JCO.2003.12.039

    CAS  PubMed  Google Scholar 

  • Burgert EO Jr, Nesbit ME, Garnsey LA, Gehan EA, Herrmann J, Vietti TJ et al (1990) Multimodal therapy for the management of nonpelvic, localized Ewing’s sarcoma of bone: intergroup study IESS-II. J Clin Oncol 8(9):1514–1524

    PubMed  Google Scholar 

  • Burke MJ, Walterhouse DO, Jacobsohn DA, Duerst RE, Kletzel M (2007) Tandem high-dose chemotherapy with autologous peripheral hematopoietic progenitor cell rescue as consolidation therapy for patients with high-risk Ewing family tumors. Pediatr Blood Cancer 49(2):196–198. doi:10.1002/pbc.21182

    PubMed  Google Scholar 

  • Caceres E, Zaharia M, Valdivia S, Misad O, de la Flor J, Tejada F, Zubrod G (1984) Local control of osteogenic sarcoma by radiation and chemotherapy. Int J Radiat Oncol Biol Phys 10(1):35–39

    CAS  PubMed  Google Scholar 

  • Cade S (1955) Osteogenic sarcoma; a study based on 133 patients. J R Coll Surg Edinb 1(2):79–111

    CAS  PubMed  Google Scholar 

  • Callstrom MR, Charboneau JW, Goetz MP, Rubin J, Atwell TD, Farrell MA, Maus TP (2006) Image-guided ablation of painful metastatic bone tumors: a new and effective approach to a difficult problem. Skeletal Radiol 35(1):1–15. doi:10.1007/s00256-005-0003-2

    PubMed  Google Scholar 

  • Cangir A, Vietti TJ, Gehan EA, Burgert EO Jr, Thomas P, Tefft M, Pritchard D (1990) Ewing’s sarcoma metastatic at diagnosis. Results and comparisons of two intergroup Ewing’s sarcoma studies. Cancer 66(5):887–893

    CAS  PubMed  Google Scholar 

  • Carli M, Passone E, Perilongo G, Bisogno G (2003) Ifosfamide in pediatric solid tumors. Oncology 65(Suppl 2):99–104. doi: 73369

    CAS  PubMed  Google Scholar 

  • Carrle D, Bielack S (2009) Osteosarcoma lung metastases detection and principles of multimodal therapy. Cancer Treat Res 152:165–184. doi:10.1007/978-1-4419-0284-9_8

    PubMed  Google Scholar 

  • Carter SR, Grimer RJ, Sneath RS, Matthews HR (1991) Results of thoracotomy in osteogenic sarcoma with pulmonary metastases. Thorax 46(10):727–731

    CAS  PubMed Central  PubMed  Google Scholar 

  • Casey DA, Wexler LH, Merchant MS, Chou AJ, Merola PR, Price AP, Meyers PA (2009) Irinotecan and temozolomide for Ewing sarcoma: the Memorial Sloan-Kettering experience. Pediatr Blood Cancer 53(6):1029–1034. doi:10.1002/pbc.22206

    PubMed  Google Scholar 

  • Chao J, Budd GT, Chu P, Frankel P, Garcia D, Junqueira M, Chow WA (2010) Phase II clinical trial of imatinib mesylate in therapy of KIT and/or PDGFRalpha-expressing Ewing sarcoma family of tumors and desmoplastic small round cell tumors. Anticancer Res 30(2):547–552

    CAS  PubMed  Google Scholar 

  • Chawla SP, Staddon AP, Baker LH, Schuetze SM, Tolcher AW, D’Amato GZ, Demetri GD (2012) Phase II study of the mammalian target of rapamycin inhibitor ridaforolimus in patients with advanced bone and soft tissue sarcomas. J Clin Oncol 30(1):78–84. doi:10.1200/JCO.2011.35.6329

    CAS  PubMed  Google Scholar 

  • Chi SN, Conklin LS, Qin J, Meyers PA, Huvos AG, Healey JH, Gorlick R (2004) The patterns of relapse in osteosarcoma: the Memorial Sloan-Kettering experience. Pediatr Blood Cancer 42(1):46–51. doi:10.1002/pbc.10420

    PubMed  Google Scholar 

  • Chou AJ, Gorlick R (2006) Chemotherapy resistance in osteosarcoma: current challenges and future directions. Expert Rev Anticancer Ther 6(7):1075–1085. doi:10.1586/14737140.6.7.1075

    CAS  PubMed  Google Scholar 

  • Chou AJ, Merola PR, Wexler LH, Gorlick RG, Vyas YM, Healey JH, Meyers PA (2005) Treatment of osteosarcoma at first recurrence after contemporary therapy: the Memorial Sloan-Kettering Cancer Center experience. Cancer 104(10):2214–2221. doi:10.1002/cncr.21417

    PubMed  Google Scholar 

  • Chou AJ, Kleinerman ES, Krailo MD, Chen Z, Betcher DL, Healey JH, Children’s Oncology G (2009) Addition of muramyl tripeptide to chemotherapy for patients with newly diagnosed metastatic osteosarcoma: a report from the Children’s Oncology Group. Cancer 115(22):5339–5348. doi:10.1002/cncr.24566

    CAS  PubMed Central  PubMed  Google Scholar 

  • Chou AJ, Gupta R, Bell MD, Riewe KO, Meyers PA, Gorlick R (2013) Inhaled lipid cisplatin (ILC) in the treatment of patients with relapsed/progressive osteosarcoma metastatic to the lung. Pediatr Blood Cancer 60(4):580–586. doi:10.1002/pbc.24438

    CAS  PubMed  Google Scholar 

  • Ciernik IF, Niemierko A, Harmon DC, Kobayashi W, Chen YL, Yock TI, Delaney TF (2011) Proton-based radiotherapy for unresectable or incompletely resected osteosarcoma. Cancer 117(19):4522–4530. doi:10.1002/cncr.26037

    PubMed Central  PubMed  Google Scholar 

  • Corby RR, Stacy GS, Peabody TD, Dixon LB (2008) Radiofrequency ablation of solitary eosinophilic granuloma of bone. AJR Am J Roentgenol 190(6):1492–1494. doi:10.2214/AJR.07.3415

    PubMed  Google Scholar 

  • Cotterill SJ, Ahrens S, Paulussen M, Jurgens HF, Voute PA, Gadner H, Craft AW (2000) Prognostic factors in Ewing’s tumor of bone: analysis of 975 patients from the European Intergroup Cooperative Ewing’s Sarcoma Study Group. J Clin Oncol 18(17):3108–3114

    CAS  PubMed  Google Scholar 

  • Craft A, Cotterill S, Malcolm A, Spooner D, Grimer R, Souhami R, Lewis I (1998) Ifosfamide-containing chemotherapy in Ewing’s sarcoma: the Second United Kingdom Children’s Cancer Study Group and the Medical Research Council Ewing’s Tumor study. J Clin Oncol 16(11):3628–3633

    CAS  PubMed  Google Scholar 

  • Dass CR, Choong PF (2007) Zoledronic acid inhibits osteosarcoma growth in an orthotopic model. Mol Cancer Ther 6(12 Pt 1):3263–3270. doi:10.1158/1535-7163.MCT-07-0546

    CAS  PubMed  Google Scholar 

  • de Moor NG (1975) Osteosarcoma a review of 72 cases treated by megavoltage radiation therapy, with or without surgery. S Afr J Surg 13(3):137–146

    PubMed  Google Scholar 

  • DeLaney TF, Park L, Goldberg SI, Hug EB, Liebsch NJ, Munzenrider JE, Suit HD (2005) Radiotherapy for local control of osteosarcoma. Int J Radiat Oncol Biol Phys 61(2):492–498. doi:10.1016/j.ijrobp.2004.05.051

    PubMed  Google Scholar 

  • Diaz-Montero CM, Wygant JN, McIntyre BW (2006) PI3-K/Akt-mediated anoikis resistance of human osteosarcoma cells requires Src activation. Eur J Cancer 42(10):1491–1500. doi:10.1016/j.ejca.2006.03.007

    CAS  PubMed  Google Scholar 

  • DuBois SG, Krailo MD, Lessnick SL, Smith R, Chen Z, Marina N, Children’s Oncology G. (2009) Phase II study of intermediate-dose cytarabine in patients with relapsed or refractory Ewing sarcoma: a report from the Children’s Oncology Group. Pediatr Blood Cancer 52(3):324–327. doi:10.1002/pbc.21822

    PubMed Central  PubMed  Google Scholar 

  • Duffaud F, Digue L, Mercier C, Dales JP, Baciuchka-Palmaro M, Volot F, Favre R (2003) Recurrences following primary osteosarcoma in adolescents and adults previously treated with chemotherapy. Eur J Cancer 39(14):2050–2057

    CAS  PubMed  Google Scholar 

  • Elias AD, Eder JP, Shea T, Begg CB, Frei E 3rd, Antman KH (1990) High-dose ifosfamide with mesna uroprotection: a phase I study. J Clin Oncol 8(1):170–178

    CAS  PubMed  Google Scholar 

  • Ellis PM, Tattersall MH, McCaughan B, Stalley P (1997) Osteosarcoma and pulmonary metastases: 15-year experience from a single institution. Aust N Z J Surg 67(9):625–629

    CAS  PubMed  Google Scholar 

  • Ellis GK, Bone HG, Chlebowski R, Paul D, Spadafora S, Smith J, Jun S (2008) Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer. J Clin Oncol 26(30):4875–4882. doi:10.1200/JCO.2008.16.3832

    CAS  PubMed  Google Scholar 

  • Erkizan HV, Kong Y, Merchant M, Schlottmann S, Barber-Rotenberg JS, Yuan L, Toretsky JA (2009) A small molecule blocking oncogenic protein EWS-FLI1 interaction with RNA helicase A inhibits growth of Ewing’s sarcoma. Nat Med 15(7):750–756. doi:10.1038/nm.1983

    CAS  PubMed Central  PubMed  Google Scholar 

  • Esiashvili N, Goodman M, Marcus RB Jr (2008) Changes in incidence and survival of Ewing sarcoma patients over the past 3 decades: surveillance epidemiology and end results data. J Pediatr Hematol Oncol 30(6):425–430. doi:10.1097/MPH.0b013e31816e22f3

    PubMed  Google Scholar 

  • Farhat R, Raad R, Khoury NJ, Feghaly J, Eid T, Muwakkit S, Saab R (2013) Cyclophosphamide and topotecan as first-line salvage therapy in patients with relapsed Ewing sarcoma at a single institution. J Pediatr Hematol Oncol 35(5):356–360. doi:10.1097/MPH.0b013e318270a343

    CAS  PubMed  Google Scholar 

  • Ferrari S, Bacci G, Picci P, Mercuri M, Briccoli A, Pinto D, Brach del Prever A (1997) Long-term follow-up and post-relapse survival in patients with non-metastatic osteosarcoma of the extremity treated with neoadjuvant chemotherapy. Ann Oncol 8(8):765–771

    CAS  PubMed  Google Scholar 

  • Ferrari S, Briccoli A, Mercuri M, Bertoni F, Picci P, Tienghi A, Bacci G (2003) Postrelapse survival in osteosarcoma of the extremities: prognostic factors for long-term survival. J Clin Oncol 21(4):710–715

    PubMed  Google Scholar 

  • Fischmeister G, Zoubek A, Jugovic D, Witt V, Ladenstein R, Fritsch G, Kovar H (1999) Low incidence of molecular evidence for tumour in PBPC harvests from patients with high risk Ewing tumours. Bone Marrow Transplant 24(4):405–409. doi:10.1038/sj.bmt.1701924

    CAS  PubMed  Google Scholar 

  • Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M, de Bono JS (2009) Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 361(2):123–134. doi:10.1056/NEJMoa0900212

    CAS  PubMed  Google Scholar 

  • Fouladi M, Park JR, Stewart CF, Gilbertson RJ, Schaiquevich P, Sun J, Adamson PC (2010) Pediatric phase I trial and pharmacokinetic study of vorinostat: a Children’s Oncology Group phase I consortium report. J Clin Oncol 28(22):3623–3629. doi:10.1200/JCO.2009.25.9119

    CAS  PubMed Central  PubMed  Google Scholar 

  • Foulkes WD, Smith IE, Reis-Filho JS (2010) Triple-negative breast cancer. N Engl J Med 363(20):1938–1948. doi:10.1056/NEJMra1001389

    CAS  PubMed  Google Scholar 

  • Fox E, Aplenc R, Bagatell R, Chuk MK, Dombi E, Goodspeed W, Balis FM (2010) A phase 1 trial and pharmacokinetic study of cediranib, an orally bioavailable pan-vascular endothelial growth factor receptor inhibitor, in children and adolescents with refractory solid tumors. J Clin Oncol 28(35):5174–5181. doi:10.1200/JCO.2010.30.9674

    CAS  PubMed Central  PubMed  Google Scholar 

  • Fox E, Patel S, Wathen JK, Schuetze S, Chawla S, Harmon D, Helman LJ (2012) Phase II study of sequential gemcitabine followed by docetaxel for recurrent Ewing sarcoma, osteosarcoma, or unresectable or locally recurrent chondrosarcoma: results of Sarcoma Alliance for Research Through Collaboration Study 003. Oncologist 17(3):321. doi:10.1634/theoncologist.2010-0265

    PubMed Central  PubMed  Google Scholar 

  • Friedlander PA, Bansal R, Schwartz L, Wagman R, Posner J, Kemeny N (2004) Gemcitabine-related radiation recall preferentially involves internal tissue and organs. Cancer 100(9):1793–1799. doi:10.1002/cncr.20229

    PubMed  Google Scholar 

  • Friedman MA, Carter SK (1972) The therapy of osteogenic sarcoma: current status and thoughts for the future. J Surg Oncol 4(5):482–510

    CAS  PubMed  Google Scholar 

  • Fu XH, Li J, Zou Y, Hong YR, Fu ZX, Huang JJ, Zheng S (2011) Endostar enhances the antineoplastic effects of combretastatin A4 phosphate in an osteosarcoma xenograft. Cancer Lett 312(1):109–116. doi:10.1016/j.canlet.2011.08.008

    CAS  PubMed  Google Scholar 

  • Fuchs N, Bielack SS, Epler D, Bieling P, Delling G, Korholz D, Winkler K (1998) Long-term results of the co-operative German-Austrian-Swiss osteosarcoma study group’s protocol COSS-86 of intensive multidrug chemotherapy and surgery for osteosarcoma of the limbs. Ann Oncol 9(8):893–899

    CAS  PubMed  Google Scholar 

  • Gaitan-Yanguas M (1981) A study of the response of osteogenic sarcoma and adjacent normal tissues to radiation. Int J Radiat Oncol Biol Phys 7(5):593–595

    CAS  PubMed  Google Scholar 

  • Garnett MJ, Edelman EJ, Heidorn SJ, Greenman CD, Dastur A, Lau KW, Benes CH (2012) Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature 483(7391):570–575. doi:10.1038/nature11005

    CAS  PubMed Central  PubMed  Google Scholar 

  • Giuliano AE, Feig S, Eilber FR (1984) Changing metastatic patterns of osteosarcoma. Cancer 54(10):2160–2164

    CAS  PubMed  Google Scholar 

  • Glade Bender JL, Adamson PC, Reid JM, Xu L, Baruchel S, Shaked Y, Children’s Oncology Group, S (2008) Phase I trial and pharmacokinetic study of bevacizumab in pediatric patients with refractory solid tumors: a Children’s Oncology Group Study. J Clin Oncol 26(3):399–405. doi:10.1200/JCO.2007.11.9230

    PubMed  Google Scholar 

  • Goetz MP, Callstrom MR, Charboneau JW, Farrell MA, Maus TP, Welch TJ, Rubin J (2004) Percutaneous image-guided radiofrequency ablation of painful metastases involving bone: a multicenter study. J Clin Oncol 22(2):300–306. doi:10.1200/JCO.2004.03.097

    PubMed  Google Scholar 

  • Goldsby RE, Fan TM, Villaluna D, Wagner LM, Isakoff MS, Meyer J, Marina N (2013) Feasibility and dose discovery analysis of zoledronic acid with concurrent chemotherapy in the treatment of newly diagnosed metastatic osteosarcoma: a report from the Children’s Oncology Group. Eur J Cancer 49(10):2384–2391. doi:10.1016/j.ejca.2013.03.018

    CAS  PubMed Central  PubMed  Google Scholar 

  • Goorin AM, Delorey MJ, Lack EE, Gelber RD, Price K, Cassady JR et al (1984) Prognostic significance of complete surgical resection of pulmonary metastases in patients with osteogenic sarcoma: analysis of 32 patients. J Clin Oncol 2(5):425–431

    CAS  PubMed  Google Scholar 

  • Goorin AM, Shuster JJ, Baker A, Horowitz ME, Meyer WH, Link MP (1991) Changing pattern of pulmonary metastases with adjuvant chemotherapy in patients with osteosarcoma: results from the multiinstitutional osteosarcoma study. J Clin Oncol 9(4):600–605

    CAS  PubMed  Google Scholar 

  • Goorin AM, Harris MB, Bernstein M, Ferguson W, Devidas M, Siegal GP, Grier HE (2002) Phase II/III trial of etoposide and high-dose ifosfamide in newly diagnosed metastatic osteosarcoma: a pediatric oncology group trial. J Clin Oncol 20(2):426–433

    CAS  PubMed  Google Scholar 

  • Gorlick R, Meyers PA (2003) Osteosarcoma necrosis following chemotherapy: innate biology versus treatment-specific. J Pediatr Hematol Oncol 25(11):840–841

    PubMed  Google Scholar 

  • Grier HE, Krailo MD, Tarbell NJ, Link MP, Fryer CJ, Pritchard DJ, Miser JS (2003) Addition of ifosfamide and etoposide to standard chemotherapy for Ewing’s sarcoma and primitive neuroectodermal tumor of bone. N Engl J Med 348(8):694–701. doi:10.1056/NEJMoa020890

    CAS  PubMed  Google Scholar 

  • Grohar PJ, Woldemichael GM, Griffin LB, Mendoza A, Chen QR, Yeung C, Helman LJ (2011) Identification of an inhibitor of the EWS-FLI1 oncogenic transcription factor by high-throughput screening. J Natl Cancer Inst 103(12):962–978. doi:10.1093/jnci/djr156

    CAS  PubMed Central  PubMed  Google Scholar 

  • Harting MT, Blakely ML, Jaffe N, Cox CS Jr, Hayes-Jordan A, Benjamin RS, Lally KP (2006) Long-term survival after aggressive resection of pulmonary metastases among children and adolescents with osteosarcoma. J Pediatr Surg 41(1):194–199. doi:10.1016/j.jpedsurg.2005.10.089

    PubMed  Google Scholar 

  • Hawkins DS, Arndt CA (2003) Pattern of disease recurrence and prognostic factors in patients with osteosarcoma treated with contemporary chemotherapy. Cancer 98(11):2447–2456. doi:10.1002/cncr.11799

    PubMed  Google Scholar 

  • Hawkins D, Barnett T, Bensinger W, Gooley T, Sanders J (2000) Busulfan, melphalan, and thiotepa with or without total marrow irradiation with hematopoietic stem cell rescue for poor-risk Ewing-Sarcoma-Family tumors. Med Pediatr Oncol 34(5):328–337

    CAS  PubMed  Google Scholar 

  • Hayes FA, Thompson EI, Kumar M, Hustu HO (1987) Long-term survival in patients with Ewing’s sarcoma relapsing after completing therapy. Med Pediatr Oncol 15(5):254–256

    CAS  PubMed  Google Scholar 

  • Hingorani P, Zhang W, Gorlick R, Kolb EA (2009) Inhibition of Src phosphorylation alters metastatic potential of osteosarcoma in vitro but not in vivo. Clin Cancer Res 15(10):3416–3422. doi:10.1158/1078-0432.CCR-08-1657

    CAS  PubMed  Google Scholar 

  • Hoffer FA, Daw NC, Xiong X, Anghelescu D, Krasin M, Yan X, Spunt SL (2009) A phase 1/pilot study of radiofrequency ablation for the treatment of recurrent pediatric solid tumors. Cancer 115(6):1328–1337. doi:10.1002/cncr.24158

    PubMed Central  PubMed  Google Scholar 

  • Hong SH, Youbi SE, Hong SP, Kallakury B, Monroe P, Erkizan HV, Toretsky JA (2014) Pharmacokinetic modeling optimizes inhibition of the ‘undruggable’ EWS-FLI1 transcription factor in Ewing sarcoma. Oncotarget 5(2):338–350

    PubMed Central  PubMed  Google Scholar 

  • Horowitz ME, Kinsella TJ, Wexler LH, Belasco J, Triche T, Tsokos M et al (1993) Total-body irradiation and autologous bone marrow transplant in the treatment of high-risk Ewing’s sarcoma and rhabdomyosarcoma. J Clin Oncol 11(10):1911–1918

    CAS  PubMed  Google Scholar 

  • Houghton PJ, Stewart CF, Cheshire PJ, Richmond LB, Kirstein MN, Poquette CA, Brent TP (2000) Antitumor activity of temozolomide combined with irinotecan is partly independent of O6-methylguanine-DNA methyltransferase and mismatch repair phenotypes in xenograft models. Clin Cancer Res 6(10):4110–4118

    CAS  PubMed  Google Scholar 

  • Houghton PJ, Morton CL, Kolb EA, Gorlick R, Lock R, Carol H, Smith MA (2008) Initial testing (stage 1) of the mTOR inhibitor rapamycin by the pediatric preclinical testing program. Pediatr Blood Cancer 50(4):799–805. doi:10.1002/pbc.21296

    PubMed  Google Scholar 

  • Houghton PJ, Morton CL, Gorlick R, Kolb EA, Keir ST, Reynolds CP, Smith MA (2010a) Initial testing of a monoclonal antibody (IMC-A12) against IGF-1R by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer 54(7):921–926. doi:10.1002/pbc.22367

    PubMed Central  PubMed  Google Scholar 

  • Houghton PJ, Morton CL, Gorlick R, Lock RB, Carol H, Reynolds CP, Smith MA (2010b) Stage 2 combination testing of rapamycin with cytotoxic agents by the Pediatric Preclinical Testing Program. Mol Cancer Ther 9(1):101–112. doi:10.1158/1535-7163.MCT-09-0952

    CAS  PubMed Central  PubMed  Google Scholar 

  • Hunold A, Weddeling N, Paulussen M, Ranft A, Liebscher C, Jurgens H (2006) Topotecan and cyclophosphamide in patients with refractory or relapsed Ewing tumors. Pediatr Blood Cancer 47(6):795–800. doi:10.1002/pbc.20719

    PubMed  Google Scholar 

  • Hunter KW (2004) Ezrin, a key component in tumor metastasis. Trends Mol Med 10(5):201–204. doi:10.1016/j.molmed.2004.03.001

    CAS  PubMed  Google Scholar 

  • Huth JF, Eilber FR (1989) Patterns of recurrence after resection of osteosarcoma of the extremity. Strategies for treatment of metastases. Arch Surg 124(1):122–126

    CAS  PubMed  Google Scholar 

  • Ikeda S, Sumii H, Akiyama K, Watanabe S, Ito S, Inoue H, Oda T (1989) Amplification of both c-myc and c-raf-1 oncogenes in a human osteosarcoma. Jpn J Cancer Res 80(1):6–9

    CAS  PubMed  Google Scholar 

  • Jacobs S, Fox E, Krailo M, Hartley G, Navid F, Wexler L, Widemann BC (2010) Phase II trial of ixabepilone administered daily for five days in children and young adults with refractory solid tumors: a report from the children’s oncology group. Clin Cancer Res 16(2):750–754. doi:10.1158/1078-0432.CCR-09-1906

    CAS  PubMed Central  PubMed  Google Scholar 

  • Jaffe N, Smith E, Abelson HT, Frei E 3rd (1983) Osteogenic sarcoma: alterations in the pattern of pulmonary metastases with adjuvant chemotherapy. J Clin Oncol 1(4):251–254

    CAS  PubMed  Google Scholar 

  • Jaffe N, Pearson P, Yasko AW, Lin P, Herzog C, Raymond K (2003) Single and multiple metachronous osteosarcoma tumors after therapy. Cancer 98(11):2457–2466. doi:10.1002/cncr.11800

    PubMed  Google Scholar 

  • Jones SF, Gian VG, Greco FA, Miranda FT, Shipley DL, Thompson DS, Burris HA 3rd (2003) Phase I. Trial of irinotecan and temozolomide in patients with solid tumors. Oncology (Williston Park) 17(5 Suppl 5):41–45

    Google Scholar 

  • Jordan MA, Wilson L (2004) Microtubules as a target for anticancer drugs. Nat Rev Cancer 4(4):253–265. doi:10.1038/nrc1317

    CAS  PubMed  Google Scholar 

  • Joschko MA, Webster LK, Groves J, Yuen K, Palatsides M, Ball DL, Millward MJ (1997) Enhancement of radiation-induced regrowth delay by gemcitabine in a human tumor xenograft model. Radiat Oncol Investig 5(2):62–71. doi:10.1002/(SICI)1520-6823(1997)5:2<62::AID-ROI4>3.0.CO;2-H

    CAS  PubMed  Google Scholar 

  • Juergens H, Daw NC, Geoerger B, Ferrari S, Villarroel M, Aerts I, Gualberto A (2011) Preliminary efficacy of the anti-insulin-like growth factor type 1 receptor antibody figitumumab in patients with refractory Ewing sarcoma. J Clin Oncol 29(34):4534–4540. doi:10.1200/JCO.2010.33.0670

    CAS  PubMed Central  PubMed  Google Scholar 

  • Kager L, Zoubek A, Potschger U, Kastner U, Flege S, Kempf-Bielack B, Cooperative German-Austrian-Swiss Osteosarcoma Study, G. (2003) Primary metastatic osteosarcoma: presentation and outcome of patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols. J Clin Oncol 21(10):2011–2018. doi:10.1200/JCO.2003.08.132

    PubMed  Google Scholar 

  • Kempf-Bielack B, Bielack SS, Jurgens H, Branscheid D, Berdel WE, Exner GU, Winkler K (2005) Osteosarcoma relapse after combined modality therapy: an analysis of unselected patients in the Cooperative Osteosarcoma Study Group (COSS). J Clin Oncol 23(3):559–568. doi:10.1200/JCO.2005.04.063

    PubMed  Google Scholar 

  • Khanna C, Wan X, Bose S, Cassaday R, Olomu O, Mendoza A, Helman LJ (2004) The membrane-cytoskeleton linker ezrin is necessary for osteosarcoma metastasis. Nat Med 10(2):182–186. doi:10.1038/nm982

    CAS  PubMed  Google Scholar 

  • Kinsella TJ, Glatstein E (1987) Clinical experience with intravenous radiosensitizers in unresectable sarcomas. Cancer 59(5):908–915

    CAS  PubMed  Google Scholar 

  • Kleinerman ES, Maeda M, Jaffe N (1993) Liposome-encapsulated muramyl tripeptide: a new biologic response modifier for the treatment of osteosarcoma. Cancer Treat Res 62:101–107

    CAS  PubMed  Google Scholar 

  • Kleinerman ES, Gano JB, Johnston DA, Benjamin RS, Jaffe N (1995) Efficacy of liposomal muramyl tripeptide (CGP 19835A) in the treatment of relapsed osteosarcoma. Am J Clin Oncol 18(2):93–99

    CAS  PubMed  Google Scholar 

  • Kolb EA, Kushner BH, Gorlick R, Laverdiere C, Healey JH, LaQuaglia MP, Meyers PA (2003) Long-term event-free survival after intensive chemotherapy for Ewing’s family of tumors in children and young adults. J Clin Oncol 21(18):3423–3430. doi:10.1200/JCO.2003.10.033

    CAS  PubMed  Google Scholar 

  • Kolb EA, Gorlick R, Houghton PJ, Morton CL, Lock RB, Tajbakhsh M, Smith MA (2008) Initial testing of dasatinib by the pediatric preclinical testing program. Pediatr Blood Cancer 50(6):1198–1206. doi:10.1002/pbc.21368

    PubMed  Google Scholar 

  • Kolb EA, Gorlick R, Reynolds CP, Kang MH, Carol H, Lock R, Smith MA (2013) Initial testing (stage 1) of eribulin, a novel tubulin binding agent, by the pediatric preclinical testing program. Pediatr Blood Cancer 60(8):1325–1332. doi:10.1002/pbc.24517

    CAS  PubMed Central  PubMed  Google Scholar 

  • Kolb EA, Gorlick R, Billups CA, Hawthorne T, Kurmasheva RT, Houghton PJ, Smith MA (2014) Initial testing (stage 1) of glembatumumab vedotin (CDX-011) by the pediatric preclinical testing program. Pediatr Blood Cancer 61(10):1816–1821. doi:10.1002/pbc.25099

    CAS  PubMed  Google Scholar 

  • Korholz D, Verheyen J, Kemperdick HF, Gobel U (1998) Evaluation of follow-up investigations in osteosarcoma patients: suggestions for an effective follow-up program. Med Pediatr Oncol 30(1):52–58

    CAS  PubMed  Google Scholar 

  • Kovar H, Aryee DN, Jug G, Henockl C, Schemper M, Delattre O, Gadner H (1996) EWS/FLI-1 antagonists induce growth inhibition of Ewing tumor cells in vitro. Cell Growth Differ 7(4):429–437

    CAS  PubMed  Google Scholar 

  • Kurzrock R, Patnaik A, Aisner J, Warren T, Leong S, Benjamin R, Gore L (2010) A phase I study of weekly R1507, a human monoclonal antibody insulin-like growth factor-I receptor antagonist, in patients with advanced solid tumors. Clin Cancer Res 16(8):2458–2465. doi:10.1158/1078-0432.CCR-09-3220

    CAS  PubMed  Google Scholar 

  • Kushner BH, Meyers PA (2001) How effective is dose-intensive/myeloablative therapy against Ewing’s sarcoma/primitive neuroectodermal tumor metastatic to bone or bone marrow? The Memorial Sloan-Kettering experience and a literature review. J Clin Oncol 19(3):870–880

    CAS  PubMed  Google Scholar 

  • Kushner BH, Kramer K, Modak S, Cheung NK (2006) Irinotecan plus temozolomide for relapsed or refractory neuroblastoma. J Clin Oncol 24(33):5271–5276. doi:10.1200/JCO.2006.06.7272

    CAS  PubMed  Google Scholar 

  • Labrinidis A, Hay S, Liapis V, Ponomarev V, Findlay DM, Evdokiou A (2009) Zoledronic acid inhibits both the osteolytic and osteoblastic components of osteosarcoma lesions in a mouse model. Clin Cancer Res 15(10):3451–3461. doi:10.1158/1078-0432.CCR-08-1616

    CAS  PubMed  Google Scholar 

  • Ladenstein R, Lasset C, Philip T (1992) Treatment duration before bone marrow transplantation in stage IV neuroblastoma. European Bone Marrow Transplant Group Solid Tumour Registry. Lancet 340(8824):916–917

    CAS  PubMed  Google Scholar 

  • Ladenstein R, Gadner H, Hartmann O, Pico J, Biron P, Thierry P (1995a) The European experience with megadose therapy and autologous bone marrow transplantation in solid tumors with poor prognosis Ewing sarcoma, germ cell tumors and brain tumors). Wien Med Wochenschr 145(2-3):55–57

    CAS  PubMed  Google Scholar 

  • Ladenstein R, Lasset C, Pinkerton R, Zucker JM, Peters C, Burdach S, Coze C (1995b) Impact of megatherapy in children with high-risk Ewing’s tumours in complete remission: a report from the EBMT Solid Tumour Registry. Bone Marrow Transplant 15(5):697–705

    CAS  PubMed  Google Scholar 

  • Ladenstein R, Potschger U, Le Deley MC, Whelan J, Paulussen M, Oberlin O, Jurgens H (2010) Primary disseminated multifocal Ewing sarcoma: results of the Euro-EWING 99 trial. J Clin Oncol 28(20):3284–3291. doi:10.1200/JCO.2009.22.9864

    CAS  PubMed  Google Scholar 

  • Lambert G, Bertrand JR, Fattal E, Subra F, Pinto-Alphandary H, Malvy C, Couvreur P (2000) EWS fli-1 antisense nanocapsules inhibits ewing sarcoma-related tumor in mice. Biochem Biophys Res Commun 279(2):401–406. doi:10.1006/bbrc.2000.3963

    CAS  PubMed  Google Scholar 

  • Langevin AM, Bernstein M, Kuhn JG, Blaney SM, Ivy P, Sun J, Children’s Oncology G. (2008) A phase II trial of rebeccamycin analogue (NSC #655649) in children with solid tumors: a Children’s Oncology Group study. Pediatr Blood Cancer 50(3):577–580. doi:10.1002/pbc.21274

    PubMed  Google Scholar 

  • Lanza LA, Miser JS, Pass HI, Roth JA (1987) The role of resection in the treatment of pulmonary metastases from Ewing’s sarcoma. J Thorac Cardiovasc Surg 94(2):181–187

    CAS  PubMed  Google Scholar 

  • Lawlor ER, Thiele CJ (2012) Epigenetic changes in pediatric solid tumors: promising new targets. Clin Cancer Res 18(10):2768–2779. doi:10.1158/1078-0432.CCR-11-1921

    CAS  PubMed Central  PubMed  Google Scholar 

  • Lawrence TS, Chang EY, Hahn TM, Shewach DS (1997) Delayed radiosensitization of human colon carcinoma cells after a brief exposure to 2′,2′-difluoro-2′-deoxycytidine (Gemcitabine). Clin Cancer Res 3(5):777–782

    CAS  PubMed  Google Scholar 

  • Le Cesne A, Antoine E, Spielmann M, Le Chevalier T, Brain E, Toussaint C et al (1995) High-dose ifosfamide: circumvention of resistance to standard-dose ifosfamide in advanced soft tissue sarcomas. J Clin Oncol 13(7):1600–1608

    PubMed  Google Scholar 

  • Leavey PJ, Collier AB (2008) Ewing sarcoma: prognostic criteria, outcomes and future treatment. Expert Rev Anticancer Ther 8(4):617–624. doi:10.1586/14737140.8.4.617

    CAS  PubMed  Google Scholar 

  • Leavey PJ, Mascarenhas L, Marina N, Chen Z, Krailo M, Miser J, Children’s Oncology G. (2008) Prognostic factors for patients with Ewing sarcoma (EWS) at first recurrence following multi-modality therapy: a report from the Children’s Oncology Group. Pediatr Blood Cancer 51(3):334–338. doi:10.1002/pbc.21618

    PubMed Central  PubMed  Google Scholar 

  • Leu KM, Ostruszka LJ, Shewach D, Zalupski M, Sondak V, Biermann JS, Baker LH (2004) Laboratory and clinical evidence of synergistic cytotoxicity of sequential treatment with gemcitabine followed by docetaxel in the treatment of sarcoma. J Clin Oncol 22(9):1706–1712. doi:10.1200/JCO.2004.08.043

    CAS  PubMed  Google Scholar 

  • Leung W, Chen AR, Klann RC, Moss TJ, Davis JM, Noga SJ, Civin CI (1998) Frequent detection of tumor cells in hematopoietic grafts in neuroblastoma and Ewing’s sarcoma. Bone Marrow Transplant 22(10):971–979. doi:10.1038/sj.bmt.1701471

    CAS  PubMed  Google Scholar 

  • Li Y, Li X, Fan G, Fukushi J, Matsumoto Y, Iwamoto Y, Zhu Y (2012) Impairment of p53 acetylation by EWS-Fli1 chimeric protein in Ewing family tumors. Cancer Lett 320(1):14–22. doi:10.1016/j.canlet.2012.01.018

    CAS  PubMed  Google Scholar 

  • Link MP, Goorin AM, Miser AW, Green AA, Pratt CB, Belasco JB et al (1986) The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity. N Engl J Med 314(25):1600–1606. doi:10.1056/NEJM198606193142502

    CAS  PubMed  Google Scholar 

  • Lipton A, Zheng M, Seaman J (2003) Zoledronic acid delays the onset of skeletal-related events and progression of skeletal disease in patients with advanced renal cell carcinoma. Cancer 98(5):962–969. doi:10.1002/cncr.11571

    CAS  PubMed  Google Scholar 

  • Loeb DM, Garrett-Mayer E, Hobbs RF, Prideaux AR, Sgouros G, Shokek O, Schwartz CL (2009) Dose-finding study of 153Sm-EDTMP in patients with poor-prognosis osteosarcoma. Cancer 115(11):2514–2522. doi:10.1002/cncr.24286

    CAS  PubMed Central  PubMed  Google Scholar 

  • Loeb DM, Hobbs RF, Okoli A, Chen AR, Cho S, Srinivasan S, Schwartz CL (2010) Tandem dosing of samarium-153 ethylenediamine tetramethylene phosphoric acid with stem cell support for patients with high-risk osteosarcoma. Cancer 116(23):5470–5478. doi:10.1002/cncr.25518

    PubMed Central  PubMed  Google Scholar 

  • Longhi A, Errani C, De Paolis M, Mercuri M, Bacci G (2006) Primary bone osteosarcoma in the pediatric age: state of the art. Cancer Treat Rev 32(6):423–436. doi:10.1016/j.ctrv.2006.05.005

    PubMed  Google Scholar 

  • MacEwen EG, Kurzman ID, Rosenthal RC, Smith BW, Manley PA, Roush JK, Howard PE (1989) Therapy for osteosarcoma in dogs with intravenous injection of liposome-encapsulated muramyl tripeptide. J Natl Cancer Inst 81(12):935–938

    CAS  PubMed  Google Scholar 

  • Machak GN, Tkachev SI, Solovyev YN, Sinyukov PA, Ivanov SM, Kochergina NV, Glebovskaya VV (2003) Neoadjuvant chemotherapy and local radiotherapy for high-grade osteosarcoma of the extremities. Mayo Clin Proc 78(2):147–155. doi:10.4065/78.2.147

    PubMed  Google Scholar 

  • Mahajan A, Woo SY, Kornguth DG, Hughes D, Huh W, Chang EL, Anderson P (2008) Multimodality treatment of osteosarcoma: radiation in a high-risk cohort. Pediatr Blood Cancer 50(5):976–982. doi:10.1002/pbc.21451

    PubMed  Google Scholar 

  • Maki RG (2008) Pediatric sarcomas occurring in adults. J Surg Oncol 97(4):360–368. doi:10.1002/jso.20969

    PubMed  Google Scholar 

  • Malempati S, Hawkins DS (2012) Rhabdomyosarcoma: review of the Children’s Oncology Group (COG) Soft-Tissue Sarcoma Committee experience and rationale for current COG studies. Pediatr Blood Cancer 59(1):5–10. doi:10.1002/pbc.24118

    PubMed Central  PubMed  Google Scholar 

  • Malempati S, Weigel B, Ingle AM, Ahern CH, Carroll JM, Roberts CT, Blaney SM (2012) Phase I/II trial and pharmacokinetic study of cixutumumab in pediatric patients with refractory solid tumors and Ewing sarcoma: a report from the Children’s Oncology Group. J Clin Oncol 30(3):256–262. doi:10.1200/JCO.2011.37.4355

    CAS  PubMed Central  PubMed  Google Scholar 

  • Manara MC, Landuzzi L, Nanni P, Nicoletti G, Zambelli D, Lollini PL, Scotlandi K (2007) Preclinical in vivo study of new insulin-like growth factor-I receptor–specific inhibitor in Ewing’s sarcoma. Clin Cancer Res 13(4):1322–1330. doi:10.1158/1078-0432.CCR-06-1518

    CAS  PubMed  Google Scholar 

  • Marina NM, Pratt CB, Shema SJ, Brooks T, Rao B, Meyer WH (1993) Brain metastases in osteosarcoma. Report of a long-term survivor and review of the St Jude Children’s Research Hospital experience. Cancer 71(11):3656–3660

    CAS  PubMed  Google Scholar 

  • Martinez A, Goffinet DR, Donaldson SS, Bagshaw MA, Kaplan HS (1985) Intra-arterial infusion of radiosensitizer (BUdR) combined with hypofractionated irradiation and chemotherapy for primary treatment of osteogenic sarcoma. Int J Radiat Oncol Biol Phys 11(1):123–128

    CAS  PubMed  Google Scholar 

  • Martini N, Huvos AG, Mike V, Marcove RC, Beattie EJ Jr (1971) Multiple pulmonary resections in the treatment of osteogenic sarcoma. Ann Thorac Surg 12(3):271–280

    CAS  PubMed  Google Scholar 

  • Mascarenhas L, Lyden ER, Breitfeld PP, Walterhouse DO, Donaldson SS, Paidas CN, Hawkins DS (2010) Randomized phase II window trial of two schedules of irinotecan with vincristine in patients with first relapse or progression of rhabdomyosarcoma: a report from the Children’s Oncology Group. J Clin Oncol 28(30):4658–4663. doi:10.1200/JCO.2010.29.7390

    CAS  PubMed Central  PubMed  Google Scholar 

  • Mateo-Lozano S, Tirado OM, Notario V (2003) Rapamycin induces the fusion-type independent downregulation of the EWS/FLI-1 proteins and inhibits Ewing’s sarcoma cell proliferation. Oncogene 22(58):9282–9287. doi:10.1038/sj.onc.1207081

    CAS  PubMed  Google Scholar 

  • Matsumoto Y, Tanaka K, Nakatani F, Matsunobu T, Matsuda S, Iwamoto Y (2001) Downregulation and forced expression of EWS-Fli1 fusion gene results in changes in the expression of G(1)regulatory genes. Br J Cancer 84(6):768–775. doi:10.1054/bjoc.2000.1652

    CAS  PubMed Central  PubMed  Google Scholar 

  • McCarville MB, Kaste SC, Cain AM, Goloubeva O, Rao BN, Pratt CB (2001) Prognostic factors and imaging patterns of recurrent pulmonary nodules after thoracotomy in children with osteosarcoma. Cancer 91(6):1170–1176

    CAS  PubMed  Google Scholar 

  • McClung MR, Lewiecki EM, Cohen SB, Bolognese MA, Woodson GC, Moffett AH, Group, A. M. G. B. L. S (2006) Denosumab in postmenopausal women with low bone mineral density. N Engl J Med 354:821–831. doi:10.1056/NEJMoa044459

    CAS  PubMed  Google Scholar 

  • McTiernan A, Driver D, Michelagnoli MP, Kilby AM, Whelan JS (2006) High dose chemotherapy with bone marrow or peripheral stem cell rescue is an effective treatment option for patients with relapsed or progressive Ewing’s sarcoma family of tumours. Ann Oncol 17(8):1301–1305. doi:10.1093/annonc/mdl108

    CAS  PubMed  Google Scholar 

  • Meazza C, Casanova M, Luksch R, Podda M, Favini F, Cefalo G, Ferrari A (2010) Prolonged 14-day continuous infusion of high-dose ifosfamide with an external portable pump: feasibility and efficacy in refractory pediatric sarcoma. Pediatr Blood Cancer 55(4):617–620. doi:10.1002/pbc.22596

    PubMed  Google Scholar 

  • Meyer WH, Schell MJ, Kumar AP, Rao BN, Green AA, Champion J, Pratt CB (1987) Thoracotomy for pulmonary metastatic osteosarcoma. An analysis of prognostic indicators of survival. Cancer 59(2):374–379

    CAS  PubMed  Google Scholar 

  • Meyer WH, Kun L, Marina N, Roberson P, Parham D, Rao B, Pratt CB (1992) Ifosfamide plus etoposide in newly diagnosed Ewing’s sarcoma of bone. J Clin Oncol 10(11):1737–1742

    CAS  PubMed  Google Scholar 

  • Meyers PA, Gorlick R (1997) Osteosarcoma. Pediatr Clin North Am 44(4):973–989

    CAS  PubMed  Google Scholar 

  • Meyers PA, Heller G, Vlamis V (1993) Osteosarcoma of the extremities: chemotherapy experience at Memorial Sloan-Kettering. Cancer Treat Res 62:309–322

    CAS  PubMed  Google Scholar 

  • Meyers PA, Gorlick R, Heller G, Casper E, Lane J, Huvos AG, Healey JH (1998) Intensification of preoperative chemotherapy for osteogenic sarcoma: results of the Memorial Sloan-Kettering (T12) protocol. J Clin Oncol 16(7):2452–2458

    CAS  PubMed  Google Scholar 

  • Meyers PA, Krailo MD, Ladanyi M, Chan KW, Sailer SL, Dickman PS, Gorlick RG (2001) High-dose melphalan, etoposide, total-body irradiation, and autologous stem-cell reconstitution as consolidation therapy for high-risk Ewing’s sarcoma does not improve prognosis. J Clin Oncol 19(11):2812–2820

    CAS  PubMed  Google Scholar 

  • Meyers PA, Schwartz CL, Krailo M, Kleinerman ES, Betcher D, Bernstein ML, Grier H (2005) Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate. J Clin Oncol 23(9):2004–2011. doi:10.1200/JCO.2005.06.031

    CAS  PubMed  Google Scholar 

  • Meyers PA, Schwartz CL, Krailo MD, Healey JH, Bernstein ML, Betcher D, Children’s Oncology G. (2008) Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival–a report from the Children’s Oncology Group. J Clin Oncol 26(4):633–638. doi:10.1200/JCO.2008.14.0095

    CAS  PubMed  Google Scholar 

  • Miser JS, Kinsella TJ, Triche TJ, Tsokos M, Jarosinski P, Forquer R, Magrath I (1987) Ifosfamide with mesna uroprotection and etoposide: an effective regimen in the treatment of recurrent sarcomas and other tumors of children and young adults. J Clin Oncol 5(8):1191–1198

    CAS  PubMed  Google Scholar 

  • Miser JS, Krailo MD, Tarbell NJ, Link MP, Fryer CJ, Pritchard DJ, Grier HE (2004) Treatment of metastatic Ewing’s sarcoma or primitive neuroectodermal tumor of bone: evaluation of combination ifosfamide and etoposide–a Children’s Cancer Group and Pediatric Oncology Group study. J Clin Oncol 22(14):2873–2876. doi:10.1200/JCO.2004.01.041

    CAS  PubMed  Google Scholar 

  • Miser JS, Goldsby RE, Chen Z, Krailo MD, Tarbell NJ, Link MP, Grier HE (2007) Treatment of metastatic Ewing sarcoma/primitive neuroectodermal tumor of bone: evaluation of increasing the dose intensity of chemotherapy–a report from the Children’s Oncology Group. Pediatr Blood Cancer 49(7):894–900. doi:10.1002/pbc.21233

    PubMed  Google Scholar 

  • Mora J, Cruz CO, Parareda A, de Torres C (2009) Treatment of relapsed/refractory pediatric sarcomas with gemcitabine and docetaxel. J Pediatr Hematol Oncol 31(10):723–729. doi:10.1097/MPH.0b013e3181b2598c

    CAS  PubMed  Google Scholar 

  • Mori K, Le Goff B, Berreur M, Riet A, Moreau A, Blanchard F, Heymann D (2007) Human osteosarcoma cells express functional receptor activator of nuclear factor-kappa B. J Pathol 211(5):555–562. doi:10.1002/path.2140

    CAS  PubMed  Google Scholar 

  • Nagano A, Miyamoto K, Nishimoto H, Hosoe H, Suzuki N, Shimizu K (2009) Transforaminal lumbar interbody fusion for failed Graf ligamentoplasty: a report of two cases. J Orthop Surg (Hong Kong) 17(2):220–222

    Google Scholar 

  • Naing A, LoRusso P, Fu S, Hong DS, Anderson P, Benjamin RS, Kurzrock R (2012) Insulin growth factor-receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with refractory Ewing’s sarcoma family tumors. Clin Cancer Res 18(9):2625–2631. doi:10.1158/1078-0432.CCR-12-0061

    CAS  PubMed  Google Scholar 

  • Nardin A, Lefebvre ML, Labroquere K, Faure O, Abastado JP (2006) Liposomal muramyl tripeptide phosphatidylethanolamine: targeting and activating macrophages for adjuvant treatment of osteosarcoma. Curr Cancer Drug Targets 6(2):123–133

    CAS  PubMed  Google Scholar 

  • Navid F, Billups C, Liu T, Krasin MJ, Rodriguez-Galindo C (2008a) Second cancers in patients with the Ewing sarcoma family of tumours. Eur J Cancer 44(7):983–991. doi:10.1016/j.ejca.2008.02.027

    PubMed Central  PubMed  Google Scholar 

  • Navid F, Willert JR, McCarville MB, Furman W, Watkins A, Roberts W, Daw NC (2008b) Combination of gemcitabine and docetaxel in the treatment of children and young adults with refractory bone sarcoma. Cancer 113(2):419–425. doi:10.1002/cncr.23586

    CAS  PubMed  Google Scholar 

  • Nesbit ME Jr, Gehan EA, Burgert EO Jr, Vietti TJ, Cangir A, Tefft M et al (1990) Multimodal therapy for the management of primary, nonmetastatic Ewing’s sarcoma of bone: a long-term follow-up of the First Intergroup study. J Clin Oncol 8(10):1664–1674

    PubMed  Google Scholar 

  • Newlands ES, Stevens MF, Wedge SR, Wheelhouse RT, Brock C (1997) Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials. Cancer Treat Rev 23(1):35–61

    CAS  PubMed  Google Scholar 

  • Nilbert M, Saeter G, Elomaa I, Monge OR, Wiebe T, Alvegard TA (1998) Ewing’s sarcoma treatment in Scandinavia 1984–1990–ten-year results of the Scandinavian Sarcoma Group Protocol SSGIV. Acta Oncol 37(4):375–378

    CAS  PubMed  Google Scholar 

  • Nilsson S, Larsen RH, Fossa SD, Balteskard L, Borch KW, Westlin JE, Bruland OS (2005) First clinical experience with alpha-emitting radium-223 in the treatment of skeletal metastases. Clin Cancer Res 11(12):4451–4459. doi:10.1158/1078-0432.CCR-04-2244

    CAS  PubMed  Google Scholar 

  • Nilsson S, Franzen L, Parker C, Tyrrell C, Blom R, Tennvall J, Bruland OS (2007) Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study. Lancet Oncol 8(7):587–594. doi:10.1016/S1470-2045(07)70147-X

    CAS  PubMed  Google Scholar 

  • Oberlin O, Patte C, Demeocq F, Lacombe MJ, Brunat-Mentigny M, Demaille MC, Lemerle J (1985) The response to initial chemotherapy as a prognostic factor in localized Ewing’s sarcoma. Eur J Cancer Clin Oncol 21(4):463–467

    CAS  PubMed  Google Scholar 

  • Oberlin O, Habrand JL, Zucker JM, Brunat-Mentigny M, Terrier-Lacombe MJ, Dubousset J et al (1992) No benefit of ifosfamide in Ewing’s sarcoma: a nonrandomized study of the French Society of Pediatric Oncology. J Clin Oncol 10(9):1407–1412

    CAS  PubMed  Google Scholar 

  • Oberlin O, Deley MC, Bui BN, Gentet JC, Philip T, Terrier P, French Society of Paediatric, O (2001) Prognostic factors in localized Ewing’s tumours and peripheral neuroectodermal tumours: the third study of the French Society of Paediatric Oncology (EW88 study). Br J Cancer 85(11):1646–1654. doi:10.1054/bjoc.2001.2150

    CAS  PubMed Central  PubMed  Google Scholar 

  • Oberlin O, Rey A, Desfachelles AS, Philip T, Plantaz D, Schmitt C, Societe Francaise des Cancers de, l. E. (2006) Impact of high-dose busulfan plus melphalan as consolidation in metastatic Ewing tumors: a study by the Societe Francaise des Cancers de l’Enfant. J Clin Oncol 24(24):3997–4002. doi:10.1200/JCO.2006.05.7059

    CAS  PubMed  Google Scholar 

  • Olmos D, Postel-Vinay S, Molife LR, Okuno SH, Schuetze SM, Paccagnella ML, Haluska P (2010) Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing’s sarcoma: a phase 1 expansion cohort study. Lancet Oncol 11(2):129–135. doi:10.1016/S1470-2045(09)70354-7

    CAS  PubMed Central  PubMed  Google Scholar 

  • O’Reilly KE, Rojo F, She QB, Solit D, Mills GB, Smith D, Rosen N (2006) mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 66(3):1500–1508. doi:10.1158/0008-5472.CAN-05-2925

    PubMed Central  PubMed  Google Scholar 

  • Ory B, Heymann MF, Kamijo A, Gouin F, Heymann D, Redini F (2005) Zoledronic acid suppresses lung metastases and prolongs overall survival of osteosarcoma-bearing mice. Cancer 104(11):2522–2529. doi:10.1002/cncr.21530

    CAS  PubMed  Google Scholar 

  • Palumbo R, Palmeri S, Antimi M, Gatti C, Raffo P, Villani G, Toma S (1997) Phase II study of continuous-infusion high-dose ifosfamide in advanced and/or metastatic pretreated soft tissue sarcomas. Ann Oncol 8(11):1159–1162

    CAS  PubMed  Google Scholar 

  • Pappo AS, Patel SR, Crowley J, Reinke DK, Kuenkele KP, Chawla SP, Baker LH (2011) R1507, a monoclonal antibody to the insulin-like growth factor 1 receptor, in patients with recurrent or refractory Ewing sarcoma family of tumors: results of a phase II Sarcoma Alliance for Research through Collaboration study. J Clin Oncol 29(34):4541–4547. doi:10.1200/JCO.2010.34.0000

    CAS  PubMed Central  PubMed  Google Scholar 

  • Parker C, Nilsson S, Heinrich D, Helle SI, O’Sullivan JM, Fossa SD, Investigators A (2013) Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med 369(3):213–223. doi:10.1056/NEJMoa1213755

    CAS  PubMed  Google Scholar 

  • Pastorino U, Gasparini M, Tavecchio L, Azzarelli A, Mapelli S, Zucchi V, Ravasi G (1991) The contribution of salvage surgery to the management of childhood osteosarcoma. J Clin Oncol 9(8):1357–1362

    CAS  PubMed  Google Scholar 

  • Patel SR, Vadhan-Raj S, Papadopolous N, Plager C, Burgess MA, Hays C, Benjamin RS (1997) High-dose ifosfamide in bone and soft tissue sarcomas: results of phase II and pilot studies–dose-response and schedule dependence. J Clin Oncol 15(6):2378–2384

    CAS  PubMed  Google Scholar 

  • Paulussen M, Ahrens S, Burdach S, Craft A, Dockhorn-Dworniczak B, Dunst J, Jurgens H (1998) Primary metastatic (stage IV) Ewing tumor: survival analysis of 171 patients from the EICESS studies. European Intergroup Cooperative Ewing Sarcoma Studies. Ann Oncol 9(3):275–281

    CAS  PubMed  Google Scholar 

  • Paulussen M, Ahrens S, Dunst J, Winkelmann W, Exner GU, Kotz R, Jurgens H (2001) Localized Ewing tumor of bone: final results of the cooperative Ewing’s Sarcoma Study CESS 86. J Clin Oncol 19(6):1818–1829

    CAS  PubMed  Google Scholar 

  • Perentesis J, Katsanis E, DeFor T, Neglia J, Ramsay N (1999) Autologous stem cell transplantation for high-risk pediatric solid tumors. Bone Marrow Transplant 24(6):609–615. doi:10.1038/sj.bmt.1701950

    CAS  PubMed  Google Scholar 

  • Petsas T, Megas P, Papathanassiou Z (2007) Radiofrequency ablation of two femoral head chondroblastomas. Eur J Radiol 63(1):63–67. doi:10.1016/j.ejrad.2007.03.024

    PubMed  Google Scholar 

  • Picci P, Rougraff BT, Bacci G, Neff JR, Sangiorgi L, Cazzola A et al (1993) Prognostic significance of histopathologic response to chemotherapy in nonmetastatic Ewing’s sarcoma of the extremities. J Clin Oncol 11(9):1763–1769

    CAS  PubMed  Google Scholar 

  • Picci P, Bohling T, Bacci G, Ferrari S, Sangiorgi L, Mercuri M, Bertoni F (1997) Chemotherapy-induced tumor necrosis as a prognostic factor in localized Ewing’s sarcoma of the extremities. J Clin Oncol 15(4):1553–1559

    CAS  PubMed  Google Scholar 

  • Pieper S, Ranft A, Braun-Munzinger G, Jurgens H, Paulussen M, Dirksen U (2008) Ewing’s tumors over the age of 40: a retrospective analysis of 47 patients treated according to the International Clinical Trials EICESS 92 and EURO-E.W.I.N.G. 99. Onkologie 31(12):657–663. doi:10.1159/000165361

    PubMed  Google Scholar 

  • Pignochino Y, Grignani G, Cavalloni G, Motta M, Tapparo M, Bruno S, Aglietta M (2009) Sorafenib blocks tumour growth, angiogenesis and metastatic potential in preclinical models of osteosarcoma through a mechanism potentially involving the inhibition of ERK1/2, MCL-1 and ezrin pathways. Mol Cancer 8:118. doi:10.1186/1476-4598-8-118

    PubMed Central  PubMed  Google Scholar 

  • Pratt CB, Epelman S, Jaffe N (1987) Bleomycin, cyclophosphamide, and dactinomycin in metastatic osteosarcoma: lack of tumor regression in previously treated patients. Cancer Treat Rep 71(4):421–423

    CAS  PubMed  Google Scholar 

  • Putnam JB Jr, Roth JA, Wesley MN, Johnston MR, Rosenberg SA (1983) Survival following aggressive resection of pulmonary metastases from osteogenic sarcoma: analysis of prognostic factors. Ann Thorac Surg 36(5):516–523

    PubMed  Google Scholar 

  • Reardon DA, Quinn JA, Rich JN, Desjardins A, Vredenburgh J, Gururangan S, Friedman HS (2005) Phase I trial of irinotecan plus temozolomide in adults with recurrent malignant glioma. Cancer 104(7):1478–1486. doi:10.1002/cncr.21316

    CAS  PubMed  Google Scholar 

  • Reid JM, Qu W, Safgren SL, Ames MM, Krailo MD, Seibel NL, Holcenberg J (2004) Phase I trial and pharmacokinetics of gemcitabine in children with advanced solid tumors. J Clin Oncol 22(12):2445–2451. doi:10.1200/JCO.2004.10.142

    CAS  PubMed  Google Scholar 

  • Rettew AN, Young ED, Lev DC, Kleinerman ES, Abdul-Karim FW, Getty PJ, Greenfield EM (2012) Multiple receptor tyrosine kinases promote the in vitro phenotype of metastatic human osteosarcoma cell lines. Oncogenesis 1, e34. doi:10.1038/oncsis.2012.34

    CAS  PubMed Central  PubMed  Google Scholar 

  • Ricotti L, Tesei A, De Paola F, Ulivi P, Frassineti GL, Milandri C, Zoli W (2003) In vitro schedule-dependent interaction between docetaxel and gemcitabine in human gastric cancer cell lines. Clin Cancer Res 9(2):900–905

    CAS  PubMed  Google Scholar 

  • Robinson D, Halperin N, Nevo Z (2001) Two freezing cycles ensure interface sterilization by cryosurgery during bone tumor resection. Cryobiology 43(1):4–10. doi:10.1006/cryo.2001.2312

    CAS  PubMed  Google Scholar 

  • Robinson SI, Ahmed SK, Okuno SH, Arndt CA, Rose PS, Laack NN (2013) Clinical outcomes of adult patients with relapsed Ewing sarcoma: a 30-year single-institution experience. Am J Clin Oncol. doi:10.1097/COC.0b013e318281d6ab

    Google Scholar 

  • Rodriguez-Galindo C, Billups CA, Kun LE, Rao BN, Pratt CB, Merchant TE, Pappo AS (2002a) Survival after recurrence of Ewing tumors: the St Jude Children’s Research Hospital experience, 1979–1999. Cancer 94(2):561–569. doi:10.1002/cncr.10192

    PubMed  Google Scholar 

  • Rodriguez-Galindo C, Daw NC, Kaste SC, Meyer WH, Dome JS, Pappo AS, Pratt CB (2002b) Treatment of refractory osteosarcoma with fractionated cyclophosphamide and etoposide. J Pediatr Hematol Oncol 24(4):250–255

    PubMed  Google Scholar 

  • Rosen LS, Gordon D, Kaminski M, Howell A, Belch A, Mackey J, Seaman JJ (2003) Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer 98(8):1735–1744. doi:10.1002/cncr.11701

    CAS  PubMed  Google Scholar 

  • Rosenburg SA, Flye MW, Conkle D, Seipp CA, Levine AS, Simon RM (1979) Treatment of osteogenic sarcoma. II. Aggressive resection of pulmonary metastases. Cancer Treat Rep 63(5):753–756

    CAS  PubMed  Google Scholar 

  • Roth M, Linkowski M, Tarim J, Piperdi S, Sowers R, Geller D, Gorlick R (2014) Ganglioside GD2 as a therapeutic target for antibody-mediated therapy in patients with osteosarcoma. Cancer 120(4):548–554. doi:10.1002/cncr.28461

    CAS  PubMed Central  PubMed  Google Scholar 

  • Rybak LD (2009) Fire and ice: thermal ablation of musculoskeletal tumors. Radiol Clin North Am 47(3):455–469. doi:10.1016/j.rcl.2008.12.006

    PubMed  Google Scholar 

  • Saeter G, Hoie J, Stenwig AE, Johansson AK, Hannisdal E, Solheim OP (1995) Systemic relapse of patients with osteogenic sarcoma. Prognostic factors for long term survival. Cancer 75(5):1084–1093

    CAS  PubMed  Google Scholar 

  • Sandoval C, Meyer WH, Parham DM, Kun LE, Hustu HO, Luo X, Pratt CB (1996) Outcome in 43 children presenting with metastatic Ewing sarcoma: the St. Jude Children’s Research Hospital experience, 1962 to 1992. Med Pediatr Oncol 26(3):180–185. doi:10.1002/(SICI)1096-911X(199603)26:3<180::AID-MPO6>3.0.CO;2-G

    CAS  PubMed  Google Scholar 

  • San-Julian M, Diaz-de-Rada P, Noain E, Sierrasesumaga L (2003) Bone metastases from osteosarcoma. Int Orthop 27(2):117–120. doi:10.1007/s00264-002-0407-8

    CAS  PubMed  Google Scholar 

  • Sankar S, Bell R, Stephens B, Zhuo R, Sharma S, Bearss DJ, Lessnick SL (2013) Mechanism and relevance of EWS/FLI-mediated transcriptional repression in Ewing sarcoma. Oncogene 32(42):5089–5100. doi:10.1038/onc.2012.525

    CAS  PubMed Central  PubMed  Google Scholar 

  • Santiago FR, Del Mar Castellano Garcia M, Montes JL, Garcia MR, Fernandez JM (2009) Treatment of bone tumours by radiofrequency thermal ablation. Curr Rev Musculoskelet Med 2(1):43–50. doi:10.1007/s12178-008-9042-3

    PubMed Central  PubMed  Google Scholar 

  • Sauer R, Jurgens H, Burgers JM, Dunst J, Hawlicek R, Michaelis J (1987) Prognostic factors in the treatment of Ewing’s sarcoma. The Ewing’s Sarcoma Study Group of the German Society of Paediatric Oncology CESS 81. Radiother Oncol 10(2):101–110

    CAS  PubMed  Google Scholar 

  • Saumet L, Deschamps F, Marec-Berard P, Gaspar N, Corradini N, Petit P, Brugieres L (2014) Radiofrequency ablation of metastases from osteosarcoma in patients under 25 years: the SCFE experience. Pediatr Hematol Oncol. doi:10.3109/08880018.2014.926469

    PubMed  Google Scholar 

  • Saylors RL 3rd, Stine KC, Sullivan J, Kepner JL, Wall DA, Bernstein ML, Pediatric Oncology G (2001) Cyclophosphamide plus topotecan in children with recurrent or refractory solid tumors: a Pediatric Oncology Group phase II study. J Clin Oncol 19(15):3463–3469

    CAS  PubMed  Google Scholar 

  • Schaller RT Jr, Haas J, Schaller J, Morgan A, Bleyer A (1982) Improved survival in children with osteosarcoma following resection of pulmonary metastases. J Pediatr Surg 17(5):546–550

    PubMed  Google Scholar 

  • Schuck A, Ahrens S, Paulussen M, Kuhlen M, Konemann S, Rube C, Jurgens H (2003) Local therapy in localized Ewing tumors: results of 1058 patients treated in the CESS 81, CESS 86, and EICESS 92 trials. Int J Radiat Oncol Biol Phys 55(1):168–177

    PubMed  Google Scholar 

  • Schwartz GK, Tap WD, Qin LX, Livingston MB, Undevia SD, Chmielowski B, Maki RG (2013) Cixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: a multicentre, open-label, phase 2 trial. Lancet Oncol 14(4):371–382. doi:10.1016/S1470-2045(13)70049-4

    CAS  PubMed Central  PubMed  Google Scholar 

  • Schwarz R, Bruland O, Cassoni A, Schomberg P, Bielack S (2009) The role of radiotherapy in osteosarcoma. Cancer Treat Res 152:147–164. doi:10.1007/978-1-4419-0284-9_7

    PubMed  Google Scholar 

  • Scotlandi K (2006) Targeted therapies in Ewing’s sarcoma. Adv Exp Med Biol 587:13–22

    CAS  PubMed  Google Scholar 

  • Seibel NL, Blaney SM, O’Brien M, Krailo M, Hutchinson R, Mosher RB, Reaman GH (1999) Phase I trial of docetaxel with filgrastim support in pediatric patients with refractory solid tumors: a collaborative Pediatric Oncology Branch, National Cancer Institute and Children’s Cancer Group trial. Clin Cancer Res 5(4):733–737

    CAS  PubMed  Google Scholar 

  • Shankar AG, Ashley S, Craft AW, Pinkerton CR (2003) Outcome after relapse in an unselected cohort of children and adolescents with Ewing sarcoma. Med Pediatr Oncol 40(3):141–147. doi:10.1002/mpo.10248

    CAS  PubMed  Google Scholar 

  • Shibuya H, Hamamura K, Hotta H, Matsumoto Y, Nishida Y, Hattori H, Furukawa K (2012) Enhancement of malignant properties of human osteosarcoma cells with disialyl gangliosides GD2/GD3. Cancer Sci 103(9):1656–1664. doi:10.1111/j.1349-7006.2012.02344.x

    CAS  PubMed  Google Scholar 

  • Siegel RD, Ryan LM, Antman KH (1988) Adults with Ewing’s sarcoma. An analysis of 16 patients at the Dana-Farber Cancer Institute. Am J Clin Oncol 11(6):614–617

    CAS  PubMed  Google Scholar 

  • Simon CJ, Dupuy DE (2006) Percutaneous minimally invasive therapies in the treatment of bone tumors: thermal ablation. Semin Musculoskelet Radiol 10(2):137–144. doi:10.1055/s-2006-939031

    PubMed  Google Scholar 

  • Skubitz KM (2003) Phase II trial of pegylated-liposomal doxorubicin (Doxil) in sarcoma. Cancer Invest 21(2):167–176

    CAS  PubMed  Google Scholar 

  • Smithey BE, Pappo AS, Hill DA (2002) C-kit expression in pediatric solid tumors: a comparative immunohistochemical study. Am J Surg Pathol 26(4):486–492

    PubMed  Google Scholar 

  • Soldatenkov VA, Albor A, Patel BK, Dreszer R, Dritschilo A, Notario V (1999) Regulation of the human poly(ADP-ribose) polymerase promoter by the ETS transcription factor. Oncogene 18(27):3954–3962. doi:10.1038/sj.onc.1202778

    CAS  PubMed  Google Scholar 

  • Spanos PK, Payne WS, Ivins JC, Pritchard DJ (1976) Pulmonary resection for metastatic osteogenic sarcoma. J Bone Joint Surg Am 58(5):624–628

    CAS  PubMed  Google Scholar 

  • Stahl M, Ranft A, Paulussen M, Bolling T, Vieth V, Bielack S, Dirksen U (2011) Risk of recurrence and survival after relapse in patients with Ewing sarcoma. Pediatr Blood Cancer 57(4):549–553. doi:10.1002/pbc.23040

    PubMed  Google Scholar 

  • Stewart KS, Kleinerman ES (2011) Tumor vessel development and expansion in Ewing’s sarcoma: a review of the vasculogenesis process and clinical trials with vascular-targeting agents. Sarcoma 2011:165837. doi:10.1155/2011/165837

    PubMed Central  PubMed  Google Scholar 

  • Strauss SJ, McTiernan A, Whelan JS (2004) Late relapse of osteosarcoma: implications for follow-up and screening. Pediatr Blood Cancer 43(6):692–697. doi:10.1002/pbc.20154

    PubMed  Google Scholar 

  • Subbiah V, Brown RE, Jiang Y, Buryanek J, Hayes-Jordan A, Kurzrock R, Anderson PM (2013) Morphoproteomic profiling of the mammalian target of rapamycin (mTOR) signaling pathway in desmoplastic small round cell tumor (EWS/WT1), Ewing’s sarcoma (EWS/FLI1) and Wilms’ tumor(WT1). PLoS One 8(7):e68985. doi:10.1371/journal.pone.0068985

    CAS  PubMed Central  PubMed  Google Scholar 

  • Sulzbacher I, Birner P, Trieb K, Traxler M, Lang S, Chott A (2003) Expression of platelet-derived growth factor-AA is associated with tumor progression in osteosarcoma. Mod Pathol 16(1):66–71. doi:10.1097/01.MP.0000043522.76788.0A

    PubMed  Google Scholar 

  • Sutow WW, Sullivan MP (1962) Cyclophosphamide therapy in children with Ewing’s sarcoma. Cancer Chemother Rep 23:55–60

    CAS  PubMed  Google Scholar 

  • Ta HT, Dass CR, Larson I, Choong PF, Dunstan DE (2009) A chitosan-dipotassium orthophosphate hydrogel for the delivery of Doxorubicin in the treatment of osteosarcoma. Biomaterials 30(21):3605–3613. doi:10.1016/j.biomaterials.2009.03.022

    CAS  PubMed  Google Scholar 

  • Tabone MD, Kalifa C, Rodary C, Raquin M, Valteau-Couanet D, Lemerle J (1994) Osteosarcoma recurrences in pediatric patients previously treated with intensive chemotherapy. J Clin Oncol 12(12):2614–2620

    CAS  PubMed  Google Scholar 

  • Temeck BK, Wexler LH, Steinberg SM, McClure LL, Horowitz M, Pass HI (1995) Metastasectomy for sarcomatous pediatric histologies: results and prognostic factors. Ann Thorac Surg 59(6):1385–1389; discussion 1390

    CAS  PubMed  Google Scholar 

  • Thompson RC Jr, Cheng EY, Clohisy DR, Perentesis J, Manivel C, Le CT (2002) Results of treatment for metastatic osteosarcoma with neoadjuvant chemotherapy and surgery. Clin Orthop Relat Res (397):240–247

    Google Scholar 

  • Thompson PA, Gupta M, Rosner GL, Yu A, Barrett J, Bomgaars L, Mondick J (2008) Pharmacokinetics of irinotecan and its metabolites in pediatric cancer patients: a report from the children’s oncology group. Cancer Chemother Pharmacol 62(6):1027–1037. doi:10.1007/s00280-008-0692-z

    CAS  PubMed  Google Scholar 

  • Thornton KA, Chen AR, Trucco MM, Shah P, Wilky BA, Gul N, Loeb DM (2013) A dose-finding study of temsirolimus and liposomal doxorubicin for patients with recurrent and refractory bone and soft tissue sarcoma. Int J Cancer 133(4):997–1005. doi:10.1002/ijc.28083

    CAS  PubMed  Google Scholar 

  • Toretsky JA, Connell Y, Neckers L, Bhat NK (1997a) Inhibition of EWS-FLI-1 fusion protein with antisense oligodeoxynucleotides. J Neurooncol 31(1–2):9–16

    CAS  PubMed  Google Scholar 

  • Toretsky JA, Kalebic T, Blakesley V, LeRoith D, Helman LJ (1997b) The insulin-like growth factor-I receptor is required for EWS/FLI-1 transformation of fibroblasts. J Biol Chem 272(49):30822–30827

    CAS  PubMed  Google Scholar 

  • van Putten LM (1968) Tumour reoxygenation during fractionated radiotherapy; studies with a transplantable mouse osteosarcoma. Eur J Cancer 4(2):172–182

    PubMed  Google Scholar 

  • Van Winkle P, Angiolillo A, Krailo M, Cheung YK, Anderson B, Davenport V, Cairo MS (2005) Ifosfamide, carboplatin, and etoposide (ICE) reinduction chemotherapy in a large cohort of children and adolescents with recurrent/refractory sarcoma: the Children’s Cancer Group (CCG) experience. Pediatr Blood Cancer 44(4):338–347. doi:10.1002/pbc.20227

    PubMed  Google Scholar 

  • Verrill MW, Judson IR, Harmer CL, Fisher C, Thomas JM, Wiltshaw E (1997) Ewing’s sarcoma and primitive neuroectodermal tumor in adults: are they different from Ewing’s sarcoma and primitive neuroectodermal tumor in children? J Clin Oncol 15(7):2611–2621

    CAS  PubMed  Google Scholar 

  • Wagner LM, Crews KR, Iacono LC, Houghton PJ, Fuller CE, McCarville MB, Santana VM (2004) Phase I trial of temozolomide and protracted irinotecan in pediatric patients with refractory solid tumors. Clin Cancer Res 10(3):840–848

    CAS  PubMed  Google Scholar 

  • Wagner LM, McAllister N, Goldsby RE, Rausen AR, McNall-Knapp RY, McCarville MB, Albritton K (2007) Temozolomide and intravenous irinotecan for treatment of advanced Ewing sarcoma. Pediatr Blood Cancer 48(2):132–139. doi:10.1002/pbc.20697

    PubMed  Google Scholar 

  • Wagner-Bohn A, Henze G, von Stackelberg A, Boos J (2006) Phase II study of gemcitabine in children with relapsed leukemia. Pediatr Blood Cancer 46(2):262. doi:10.1002/pbc.20632

    CAS  PubMed  Google Scholar 

  • Wan X, Mendoza A, Khanna C, Helman LJ (2005) Rapamycin inhibits ezrin-mediated metastatic behavior in a murine model of osteosarcoma. Cancer Res 65(6):2406–2411. doi:10.1158/0008-5472.CAN-04-3135

    CAS  PubMed  Google Scholar 

  • Ward WG, Mikaelian K, Dorey F, Mirra JM, Sassoon A, Holmes EC, Eckardt JJ (1994) Pulmonary metastases of stage IIB extremity osteosarcoma and subsequent pulmonary metastases. J Clin Oncol 12(9):1849–1858

    CAS  PubMed  Google Scholar 

  • Weeden S, Grimer RJ, Cannon SR, Taminiau AH, Uscinska BM, European Osteosarcoma I (2001) The effect of local recurrence on survival in resected osteosarcoma. Eur J Cancer 37(1):39–46

    CAS  PubMed  Google Scholar 

  • Weichselbaum R, Little JB, Nove J (1977) Response of human osteosarcoma in vitro to irradiation: evidence for unusual cellular repair activity. Int J Radiat Biol Relat Stud Phys Chem Med 31(3):295–299

    CAS  PubMed  Google Scholar 

  • Wexler LH, DeLaney TF, Tsokos M, Avila N, Steinberg SM, Weaver-McClure L, Horowitz ME (1996) Ifosfamide and etoposide plus vincristine, doxorubicin, and cyclophosphamide for newly diagnosed Ewing’s sarcoma family of tumors. Cancer 78(4):901–911. doi:10.1002/(SICI)1097-0142(19960815)78:4<901::AID-CNCR30>3.0.CO;2-X

    CAS  PubMed  Google Scholar 

  • Whelan J, McTiernan A, Cooper N, Wong YK, Francis M, Vernon S, Strauss SJ (2012) Incidence and survival of malignant bone sarcomas in England 1979–2007. Int J Cancer 131(4):E508–E517. doi:10.1002/ijc.26426

    CAS  PubMed  Google Scholar 

  • Wilson GD, Bentzen SM, Harari PM (2006) Biologic basis for combining drugs with radiation. Semin Radiat Oncol 16(1):2–9. doi:10.1016/j.semradonc.2005.08.001

    PubMed  Google Scholar 

  • Withrow SJ, Thrall DE, Straw RC, Powers BE, Wrigley RH, Larue SM et al (1993) Intra-arterial cisplatin with or without radiation in limb-sparing for canine osteosarcoma. Cancer 71(8):2484–2490

    CAS  PubMed  Google Scholar 

  • Wittgen BP, Kunst PW, van der Born K, van Wijk AW, Perkins W, Pilkiewicz FG, Postmus PE (2007) Phase I study of aerosolized SLIT cisplatin in the treatment of patients with carcinoma of the lung. Clin Cancer Res 13(8):2414–2421. doi:10.1158/1078-0432.CCR-06-1480

    CAS  PubMed  Google Scholar 

  • Womer RB, West DC, Krailo MD, Dickman PS, Pawel BR, Grier HE, Weiss AR (2012) Randomized controlled trial of interval-compressed chemotherapy for the treatment of localized Ewing sarcoma: a report from the Children’s Oncology Group. J Clin Oncol 30(33):4148–4154. doi:10.1200/JCO.2011.41.5703

    CAS  PubMed Central  PubMed  Google Scholar 

  • Wu D, Wan M (2012) Methylene diphosphonate-conjugated adriamycin liposomes: preparation, characteristics, and targeted therapy for osteosarcomas in vitro and in vivo. Biomed Microdevices 14(3):497–510. doi:10.1007/s10544-011-9626-3

    CAS  PubMed  Google Scholar 

  • Xu M, Xu CX, Bi WZ, Song ZG, Jia JP, Chai W, Wang Y (2013) Effects of endostar combined multidrug chemotherapy in osteosarcoma. Bone 57(1):111–115. doi:10.1016/j.bone.2013.07.035

    CAS  PubMed  Google Scholar 

  • Yang SY, Yu H, Krygier JE, Wooley PH, Mott MP (2007) High VEGF with rapid growth and early metastasis in a mouse osteosarcoma model. Sarcoma 2007:95628. doi:10.1155/2007/95628

    PubMed Central  PubMed  Google Scholar 

  • Yu AL, Uttenreuther-Fischer MM, Huang CS, Tsui CC, Gillies SD, Reisfeld RA, Kung FH (1998) Phase I trial of a human-mouse chimeric anti-disialoganglioside monoclonal antibody ch14.18 in patients with refractory neuroblastoma and osteosarcoma. J Clin Oncol 16(6):2169–2180

    CAS  PubMed  Google Scholar 

  • Yu L, Su B, Hollomon M, Deng Y, Facchinetti V, Kleinerman ES (2010) Vasculogenesis driven by bone marrow-derived cells is essential for growth of Ewing’s sarcomas. Cancer Res 70(4):1334–1343. doi:10.1158/0008-5472.CAN-09-2795

    CAS  PubMed Central  PubMed  Google Scholar 

  • Zhou LT, Liu FY, Li Y, Peng YM, Liu YH, Li J (2012) Gpnmb/osteoactivin, an attractive target in cancer immunotherapy. Neoplasma 59(1):1–5. doi:10.4149/neo_2012_001

    CAS  PubMed  Google Scholar 

  • Zwerdling T, Krailo M, Monteleone P, Byrd R, Sato J, Dunaway R, Children’s Oncology G. (2006) Phase II investigation of docetaxel in pediatric patients with recurrent solid tumors: a report from the Children’s Oncology Group. Cancer 106(8):1821–1828. doi:10.1002/cncr.21779

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Pediatric Hematology/Oncology, Shands Hospital for Children, University of Florida, 1515 SW Archer Road, Gainesville, FL, 32608, USA

    Joanne Lagmay MD

  2. Division of Hematology/Oncology/BMT, Nationwide Children’s Hospital, 700 Children’s Drive, Columbus, OH, 43205, USA

    Nicholas D. Yeager MD

Authors
  1. Joanne Lagmay MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Nicholas D. Yeager MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Joanne Lagmay MD .

Editor information

Editors and Affiliations

  1. Division of Pediatric Hematology/Oncology/Blood and Marrow Transplantation, Nationwide Children’s Hospital, Columbus, Ohio, USA

    Timothy P. Cripe

  2. Division of Pediatric Hematology/Oncology/Blood and Marrow Transplantation, Nationwide Children’s Hospital, Columbus, Ohio, USA

    Nicholas D. Yeager

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Lagmay, J., Yeager, N.D. (2015). Recurrent Bone Tumors. In: Cripe, T., Yeager, N. (eds) Malignant Pediatric Bone Tumors - Treatment & Management. Pediatric Oncology. Springer, Cham. https://doi.org/10.1007/978-3-319-18099-1_14

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-18099-1_14

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-18098-4

  • Online ISBN: 978-3-319-18099-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation